Effect of RAS Blockers on CKD Progression in Elderly Patients With Non Proteinuric Nephropathies (PROERCAN01)
- Conditions
- Renal Insufficiency, ChronicProteinuria
- Interventions
- Registration Number
- NCT03195023
- Lead Sponsor
- Hospital General Universitario Gregorio Marañon
- Brief Summary
This study evaluates the effect of renin-angiotensin blockers on chronic kidney disease progression in elderly (\>65 years old) patients with non-proteinuric nephropathies. Half of the patients will receive angiotensin converting enzyme inhibitors, while the other half will not receive them. Renal function, proteinuria and cardiovascular events will be follow up during a three year period.
- Detailed Description
STUDY DESIGN: Open, multicentre, prospective, parallel-group, randomized controlled study comparing the effect of an angiotensin converting enzyme inhibitor (ACEI) vs standard antihypertensive treatment without ACEI, in the progression of renal disease in elderly patients with non-proteinuric 3-4 stage chronic renal disease.
Elderly patients (\> 65 years) with moderate-severe non-proteinuric chronic renal disease (estimated Glomerular Filtrate Rate between 19-59 ml per minute per 1.73 m2 using the Chronic Kidney Disease Epidemiology Collaboration Group equation) and urine-creatinine rate \< 30 mg/g, will be included. They will be randomly assigned in a 1:1 ratio to receive ACEI or standard antihypertensive treatment. Patients will be followed up for 3 years.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 106
-
Age >65 years
-
Chronic kidney disease stage 3 or 4 (GFR measured by CKD-EPI 15-59 ml/min/1,73 m2)
-
Albumine/creatinine index < 30 mg/g in simple urine sample or albuminuria < 30 mg/day in 24-hour urine sample.
-
Previous hypertensive treatment::
- patients who have not received RAS blockers in the three months prior to inclusion can be included
- patients who are receiving RAS blockers could be included after one month washout period
- Diabetes mellitus (type 1 or 2)
- Glomerulopathy
- Chronic heart failure or coronary heart disease
- Poorly controlled hypertension (>160/100 mmHg)
- Monorrenal
- Active malignant neoplasia (except skin cancer different from melanoma). Patients who have been free of malignancy for the last 5 years could be included.
- Chronic symptomatic or not controlled inflammatory disease (eg rheumatoid arthritis, Chron disease, ulcerative colitis or systemic lupus erythematosus)
- Chronic liver disease
- Allergy or intolerance to renin angiotensin system blockers or calcium channel blockers
- Hepatitis B, C or HIV infection
- Immunosuppressive treatment in the 3 months prior to inclusion
- Hospitalization of any cause in the three months prior to inclusion
- Rapidly progressive kidney disease (decline in GFR >5ml/min/1.73 m2/year)
- Inability to sign the informed consent
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description RAS Blockers Lisinopril Patients in this arm will receive Lisinopril 20mg/day Non RAS Blockers Amlodipine Patients in this arm will receive Amlodipine 10mg/day or Lercanidipine 20mg/day +/- diuretics
- Primary Outcome Measures
Name Time Method Chronic kidney disease progression 3 years Increase of baseline creatinine during follow up period
- Secondary Outcome Measures
Name Time Method Security of RAS blockers in elderly patients 3 years Evaluate the frequency of acute kidney failure (\>Cr 0.3 mg/dl)
Effects of RAS blockers on cardiovascular risk in elderly patients 3 years Evaluate and classify cardiovascular events (heart failure, acute coronary syndrome, peripheral vasculopathy) during the follow up period
Effect of RAS blockers on mortality in elderly patients 3 years Evaluate the number and cause of deaths in the study population
Trial Locations
- Locations (1)
Gregorio Maranon Hospital
🇪🇸Madrid, Spain